Most Read News

Glenmark had previously announced that the United States Food and Drug Administration (USFDA) had tentatively approved their generic Axitinib Tablets.

As of now, the National Monetization Pipeline (NMP) has allowed the government to monetize assets worth Rs 33,422 crore, with the Coal Ministry topping the list with Rs 17,000 crore

This simulator will help the Urologist and patient to understand treatment of infertility and andrology more efficiently.

Lender asserts to be the first company in GIFT City to provide these products

The frontline equity benchmarks pared all the early losses and traded with minor gains in the morning trade. The Nifty scaled above the 18,200 level. Metal shares snap its four days declining trend. At 10:30 IST, the barometer index, the S&P BSE Sensex, was up 168.23 points or 0.28% to 61,313.07. The Nifty 50 index added 47.45 points or 0.26% to 18,207.40. In the broader […]

Glenmark Pharmaceuticals rose 1.32% to Rs 417 after the drug maker and its US arm, Glenmark Pharmaceuticals Inc. have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. (Pfizer) for Axitinib Tablets.

The platform has a high level of localization and was created by Bajaj Auto specifically for Yulu Bikes with the latter's technology inputs.

The company stated that it is confident that with his international market experience and track record of driving customer excellence, Lance will maintain Mercedes-growth Benz's momentum in India.

The public issue is priced at a price band of Rs559 per share to Rs587 per share respectively having a face value of Rs10 each.

Shares of Kaynes Technology India were currently trading at Rs 704.30, representing a premium of 19.98% as compared with the issue price of Rs 587.